The Prostate Specific Membrane Antigen – or PSMA – is a highly abundant membrane-bound antigen of the vast majority of prostate cancer cells. We produce ligands that specifically bind to this antigen and that can be used in the diagnostic and therapy of prostate cancer. [68Ga]PSMA-11 and [18F]PSMA-1007 are two compounds being used for diagnostic purposes in clinics due to their relatively short half-lifes. In contrast, [177Lu]PSMA-617 has a longer half-life and is therefore a promising compound being currently evaluated as a theragnostic agent in different clinical studies.
[68Ga]PSMA-11 is a biomarker for diagnostics. Generator-produced Gallium-68 (half-life 68 min)
is used for the synthesis of [68Ga]PSMA-11.
First 68Ga3+ ions are isolated and labelled with the PSMA-11 peptide. Then the product is purified by cartridge cleaning and sterile filtration. The radiochemical yield of [68Ga]PSMA-11 is typically 50-80% (non decay-corrected). For more information please click here and here.
Kits and cassettes for the production of [68Ga]PSMA-11 are available for following radiotracer modules:
|Synthesizer||product numbers (cassette, kit)|
|GE TRACERlab MXFDG||PEGA-0053|
|ORA Neptis Plug/Perform||PEGA-0053|
|ORA Neptis Mosaic RS||PEGA-0053|
|Siemens EXPLORA ONE||PEGA-0053|
|Elysia-Raytest GAIA||RT-101, RT-01-H|
|ITG Ga-68 platform||available only through ITG|
|Eckert & Ziegler Modular-Lab easy||available only through Eckert & Ziegler|
|Eckert & Ziegler Modular-Lab PharmTracer||available only through Eckert & Ziegler|
[18F]PSMA-1007 is a flourine-based PSMA-ligand and used for diagnostics (18F half-life 110 min).
Compared to [68Ga]PSMA-11 it provides a better resolution in the PET image and has a longer half-life.
Moreover, the product allows a higher amount of patient dose per production cycle.
[18F]PSMA-1007 is synthesized in a one-step procedure and purified by cartridge cleaning, hence there is no need for a HPLC purification. The radiochemical yield of purified and formulated [18F]PSMA-1007 is typically within 20-40% (non decay-corrected).
The [18F]PSMA-1007 production is a reliable and convenient method for routine clinical production and the product shows high radiochemical purity and stability. For more information please click here.
The fully automated process has been established on following radiotracer synthesizers:
|GE TRACERlab MXFDG||PEPS-0095-H||PEPS-0095-R|
|ORA Neptis Plug/Perform||PEPS-0095-H||PEPS-0095-R|
|ORA Neptis Mosaic RS||PEPS-0095-H||PEPS-0095-R|
|Siemens EXPLORA ONE||PEPS-0095-H||PEPS-0095-R|
|Trasis AllinOne||available only through Trasis||PEPS-0095-R|
[177Lu]PSMA-617 is used as theragnostic agent due to its half-life time of 6.7 days and its physical decay properties. ABX holds an exclusive, world-wide licence of [177Lu]PSMA-617. Currently ABX aims to get a manufacturing authorization of [177Lu]PSMA-617 in order to launch it within the framework of a clinical study.